US PTAB IP Litigation
2,587 annotated decisions
Page 108 of 108 · 2,587 total
Samsung Electronics Co., Ltd. et al. v.Oura Health Oy et al.
The PTAB granted institution for a high-stakes IPR concerning wearable biosensor technology, specifically smart rings. The Board found sufficient evidence of obviousness (103) and anticipation (102) to proceed with trial on 17 claims.
Samsung Electronics Co., Ltd. et al. v.Oura Health Oy et al.
The PTAB denied an IPR petition filed by Samsung against Oura Health because the patent owner had disclaimed all challenged claims.
Samsung Electronics Co., Ltd. et al. v.Oura Health Oy et al.
The PTAB denied an IPR petition filed by Samsung against Oura Health because the patent owner had disclaimed all challenged claims. This denial was based on procedural rules regarding pre-institution claim disclaimer.
Simpson Strong-Tie Company Inc. et al. v.Columbia Insurance Company et al.
The PTAB decided to institute PGR proceedings, finding that the Petitioner successfully overcame arguments of Examiner error regarding prior art combinations and claim construction issues. The dispute centers on fire-resistant wall assemblies and truss hangers, with the Board issuing preliminary determinations on key terms like 'planar extension plate' and 'bounding.'
UATP IP, LLC et al. v.Slick Slide LLC
UATP IP successfully challenged the patentability of claims related to low-friction slide systems and mesh layers. The PTAB granted institution after finding likelihood of unpatentability, moving the case toward trial preparation while providing preliminary claim construction guidance on key terms.
Catalyst OrthoScience Inc. v.Shoulder Innovations, Inc.
The PTAB denied Catalyst OrthoScience's Post-Grant Review of Shoulder Innovations' reverse shoulder implant patent (12,023,254). The denial was based on the advanced stage and significant overlap with co-pending district court litigation.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully challenged Halozyme, Inc.'s patent on modified PH20 polypeptides in a PGR proceeding. The Board found likelihood of prevailing based on arguments regarding the genus's scope and potential lack of enablement/obviousness.
Intelligent Wellhead Systems, Inc. et al. v.Downing Wellhead Equipment, LLC et al.
The PTAB instituted PGR on claims 1-78 of the '952 patent after reviewing multiple grounds, including eligibility (§ 101), obviousness (§ 103), and written description/enablement (§ 112). The Board found a likelihood of success for Petitioner despite arguments from Patent Owner regarding prior art limitations.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully petitioned the PTAB against Halozyme, Inc.'s '298 patent covering modified PH20 polypeptides. The Board granted institution despite challenges based on Written Description and Enablement, allowing the dispute to proceed to trial.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully challenged Halozyme, Inc.'s claims regarding modified PH20 polypeptides in a PTAB decision. The Board instituted trial based on enablement and written description grounds, finding that the broad genus of claimed molecules required undue experimentation to identify active variants.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
The PTAB instituted the PGR petition challenging Halozyme's patent covering modified PH20 polypeptides. The Board found that the claims were not sufficiently supported by the specification regarding enablement and obviousness, despite Petitioner's arguments about the genus size.
ITM Isotope Technologies Munich SE v.The Johns Hopkins University et al.
ITM Isotope Technologies Munich SE challenged The Johns Hopkins University's claims regarding FAP-α targeting moieties based on obviousness and patentability issues (103/112). The Board instituted the PGR, finding that the claims face significant challenges related to enablement and indefiniteness.
Therabody, Inc. v.Hyperice IP Subco, LLC et al.
Therabody successfully challenged Hyperice's patent claims in a PTAB proceeding focused on massaging devices. The Board found likelihood of unpatentability based on obviousness and statutory deficiencies, particularly regarding the combination of prior art references.
Kubota North America Corporation et al. v.Vermeer Manufacturing Company
Kubota North America Corporation successfully petitioned PGR against Vermeer Manufacturing Company's patent for agricultural machinery, leading to institution on all 11 challenged claims. The Board found sufficient evidence of anticipation and obviousness based on prior art references like KR996.
Micron Technology, Inc. et al. v.Yangtze Memory Technologies Company, Ltd.
Micron Technology successfully instituted PGR against Yangtze Memory Technologies regarding a patent on 3D memory structures. The Board found that the petitioner sufficiently demonstrated obviousness over prior art references Kim and Lee for multiple claims. This moves the dispute into trial phase, raising significant stakes in semiconductor technology licensing.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully challenged Halozyme, Inc.'s patent on enablement and obviousness grounds in a PTAB decision. The Board found that the patent documents supported a broad definition of modified PH20 polypeptides, while noting the petitioner had established a likelihood of prevailing on enablement but failed to prove obviousness.
Charles River Laboratories, Inc. v.Seikagaku Corporation
Charles River Laboratories successfully petitioned to invalidate Seikagaku Corporation's patent claims related to endotoxin detection. The Board found grounds for invalidity under 35 U.S.C. § 102 and § 112, specifically citing anticipation by a prior publication.
Multi-Color Corporation v.Brook & Whittle Ltd.
Multi-Color Corporation successfully petitioned the PTAB to institute review of claims 1-19 against Brook & Whittle Ltd.'s patent. The Board adopted a specific, technical construction for 'recyclable' based on prosecution history and found sufficient evidence across grounds including anticipation (102), obviousness (103), and indefiniteness (112).
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully challenged Halozyme, Inc.'s '590 patent on grounds of enablement and obviousness. The PTAB found the claims were overly broad regarding polypeptide scope, requiring undue experimentation for a skilled artisan.